Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,688 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists II.
Elliott JM, Carling RW, Chicchi GG, Crawforth J, Hutson PH, Jones AB, Kelly S, Marwood R, Meneses-Lorente G, Mezzogori E, Murray F, Rigby M, Royo I, Russell MG, Shaw D, Sohal B, Tsao KL, Williams B. Elliott JM, et al. Among authors: shaw d. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5752-6. doi: 10.1016/j.bmcl.2006.08.085. Epub 2006 Sep 6. Bioorg Med Chem Lett. 2006. PMID: 16950617
2-Aryl indole NK1 receptor antagonists: optimisation of indole substitution.
Cooper LC, Chicchi GG, Dinnell K, Elliott JM, Hollingworth GJ, Kurtz MM, Locker KL, Morrison D, Shaw DE, Tsao KL, Watt AP, Williams AR, Swain CJ. Cooper LC, et al. Among authors: shaw de. Bioorg Med Chem Lett. 2001 May 7;11(9):1233-6. doi: 10.1016/s0960-894x(01)00182-2. Bioorg Med Chem Lett. 2001. PMID: 11354384
4,4-Disubstituted cyclohexylamine NK(1) receptor antagonists I.
Elliott JM, Castro JL, Chicchi GG, Cooper LC, Dinnell K, Hollingworth GJ, Ridgill MP, Rycroft W, Kurtz MM, Shaw DE, Swain CJ, Tsao KL, Yang L. Elliott JM, et al. Bioorg Med Chem Lett. 2002 Jul 8;12(13):1755-8. doi: 10.1016/s0960-894x(02)00249-4. Bioorg Med Chem Lett. 2002. PMID: 12067554
Aryl sulfones: a new class of gamma-secretase inhibitors.
Teall M, Oakley P, Harrison T, Shaw D, Kay E, Elliott J, Gerhard U, Castro JL, Shearman M, Ball RG, Tsou NN. Teall M, et al. Among authors: shaw d. Bioorg Med Chem Lett. 2005 May 16;15(10):2685-8. doi: 10.1016/j.bmcl.2004.12.017. Bioorg Med Chem Lett. 2005. PMID: 15863342
4-substituted cyclohexyl sulfones as potent, orally active gamma-secretase inhibitors.
Churcher I, Beher D, Best JD, Castro JL, Clarke EE, Gentry A, Harrison T, Hitzel L, Kay E, Kerrad S, Lewis HD, Morentin-Gutierrez P, Mortishire-Smith R, Oakley PJ, Reilly M, Shaw DE, Shearman MS, Teall MR, Williams S, Wrigley JD. Churcher I, et al. Among authors: shaw de. Bioorg Med Chem Lett. 2006 Jan 15;16(2):280-4. doi: 10.1016/j.bmcl.2005.10.009. Epub 2005 Nov 3. Bioorg Med Chem Lett. 2006. PMID: 16275079
3,4-Fused cyclohexyl sulfones as gamma-secretase inhibitors.
Shaw D, Best J, Dinnell K, Nadin A, Shearman M, Pattison C, Peachey J, Reilly M, Williams B, Wrigley J, Harrison T. Shaw D, et al. Bioorg Med Chem Lett. 2006 Jun 1;16(11):3073-7. doi: 10.1016/j.bmcl.2005.12.083. Epub 2006 Apr 17. Bioorg Med Chem Lett. 2006. PMID: 16617016
Novel ROCK inhibitors for the treatment of pulmonary arterial hypertension.
Shaw D, Hollingworth G, Soldermann N, Sprague E, Schuler W, Vangrevelinghe E, Duggan N, Thomas M, Kosaka T, Waters N, van Eis MJ. Shaw D, et al. Bioorg Med Chem Lett. 2014 Oct 15;24(20):4812-7. doi: 10.1016/j.bmcl.2014.09.002. Epub 2014 Sep 6. Bioorg Med Chem Lett. 2014. PMID: 25248678
Design and Synthesis of Inhibitors of the E3 Ligase SMAD Specific E3 Ubiquitin Protein Ligase 1 as a Treatment for Lung Remodeling in Pulmonary Arterial Hypertension.
Shaw DE, Smith N, Beerli R, Cotesta S, D'Alessandro PL, Edwards AM, Lattmann R, Lizos D, Pulz R, Rooney L, Sohal B, Rynn C, Taylor J, Troxler T, Williams G, Guth S, Rowlands D. Shaw DE, et al. Among authors: d alessandro pl. J Med Chem. 2023 Jun 22;66(12):8130-8139. doi: 10.1021/acs.jmedchem.3c00229. Epub 2023 Jun 9. J Med Chem. 2023. PMID: 37294287
Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP2 Receptor Antagonist for Treatment of Asthma.
Sandham DA, Barker L, Brown L, Brown Z, Budd D, Charlton SJ, Chatterjee D, Cox B, Dubois G, Duggan N, Hall E, Hatto J, Maas J, Manini J, Profit R, Riddy D, Ritchie C, Sohal B, Shaw D, Stringer R, Sykes DA, Thomas M, Turner KL, Watson SJ, West R, Willard E, Williams G, Willis J. Sandham DA, et al. Among authors: shaw d. ACS Med Chem Lett. 2017 Apr 25;8(5):582-586. doi: 10.1021/acsmedchemlett.7b00157. eCollection 2017 May 11. ACS Med Chem Lett. 2017. PMID: 28523115 Free PMC article.
3,688 results